Currently, the third generation oral aromatase inhibitors are considered to be ideal candidates to either enhance the activity of tamoxifen or replace it entirely for the prevention of breast cancer recurrence in postmenopausal women. The gene discussed is CYP19A1; the disease is breast carcinoma.